Plans to Remove Potentially Carcinogenic Contaminants from Januvia, Janumet Outlined By Merck
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
Merck indicates it will remove nitrosamine contaminants from Januvia and Janumet by the end of 2023.
A federal judge has cleared Valsartan NDMA lawsuits to proceed after rejecting a call by defendants to reconsider the admissibility of plaintiffs' expert witnesses following the recent dismissal of Zantac…
A Bloomberg report highlights how the independent laboratory, Valisure, has consistently discovered dangerous, potentially cancer-causing chemicals in products like Zantac and sunscreen before the FDA.
The FDA has been caught off-guard by the number of drugs being recalled for nitrosamine contamination and is likely to update a 2020 guidance to better address the problem according…
Some batches of Januvia, a diabetes drug, contain high levels of nitrosamines which could increase cancer risks, the FDA warns.
Two former district judges have been appointed as valsartan settlement special masters to help bring about a resolution to the litigation.
Canadian health regulators have announced an Accuretic recall, indicating the Pfizer hypertension drug contains levels of cancer-causing chemicals above the acceptable amounts.
Valsartan and similar hypertension drugs may carry an increased risk of cancer with long-term use, according to the findings of a new study.
Dozens of batches of generic metformin are being recalled due to the presence of NDMA; a cancer-causing chemical byproduct which has led to numerous drug recalls in recent years.
A Special Master involved in valsartan litigation has determined Zhejiang Huahei Pharmacticals, the manufacturer of the active ingredient, should pay sanctions for failing to provide appropriate answers to some questions…